LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q1 2024 Earnings Call Transcript

George LeMaitre: Right. I mean it’s just — it’s a fantastic story that’s going on with shunts, which is — the main competitor were one of the two main competitors Bard left the market because they were frustrated with Brussels and the whole new CE MDR thing. So, they just said, we’re not going to support this product line. So, we’re just taking all the old units from those guys. In addition, since the CE barriers have gotten higher and higher, and we’re taking the opportunity to put in some price changes on that product line. So you got more units because Bard left and then because Bard’s gone away and there’s no new competitors coming in, you probably have better pricing. So, I think the number was something like 17% this year — this quarter, Q1.

J.J. Pellegrino: It was 27%?

George LeMaitre: Sorry, 27% was our up, Brett, in that. So, excellent activity going on there. Despite TCAR, despite stenting and all that, it’s been a fantastic run.

Brett Fishbin: All right. Appreciate taking the questions and congrats on the quarter, guys.

George LeMaitre: Thanks a lot Brett.

Operator: Thank you. I’m showing no additional questions in the queue at this time. Ladies and gentlemen, that concludes today’s conference. I would like to thank you for your participation and you may now disconnect. Have a great day.